Current therapies for multiple sclerosis (MS) reduce both relapses and relapse-associated
worsening of disability, which is assumed to be mainly associated with transient infiltration of …

Multiple sclerosis (MS) is an autoimmune disease affecting the central nervous system that
causes significant disability and healthcare burden. The treatment of MS has evolved over …

SARS-CoV-2 messenger RNA vaccination in healthy individuals generates immune
protection against COVID-19. However, little is known about SARS-CoV-2 mRNA vaccine …

Background The monoclonal antibody ublituximab enhances antibody-dependent cellular
cytolysis and produces B-cell depletion. Ublituximab is being evaluated for the treatment of …

Epidemiology and Pathophysiology of Multiple Sclerosis : CONTINUUM: Lifelong Learning in
Neurology Account Register Activate Subscription Help Subscribe American Academy of …

Astrocytes are abundant glial cells in the central nervous system (CNS) that control multiple
aspects of health and disease. Through their interactions with components of the blood …

The preclinical phase of autoimmune disorders is characterized by an initial asymptomatic
phase of varying length followed by nonspecific signs and symptoms. A variety of …

Multiple sclerosis (MS) is an immune-mediated disease of the central nervous system that
causes demyelination, axonal degeneration and astrogliosis, resulting in progressive …

Vitamin D deficiency has been associated with the risk of multiple sclerosis, disease activity
and progression. Results from in vitro experiments, animal models and analysis of human …

A small proportion of multiple sclerosis (MS) patients develop new disease activity soon after
starting anti-CD20 therapy. This activity does not recur with further dosing, possibly reflecting …